Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 415 of the 415 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
Background2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (1).”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534 · cited 2×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 2×
“Recent guidelines address bonespecific therapies (43).”
BackgroundWriting Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cited by
Items 801–883 of 883
Araújo, M. C. M. D. S., Guilhen, A. C. C., Maciel, A. D. F., Portes, B., Luciano, N. S. C., & Teixeira, A. B. (2025) · Revista Omnia Saúde · doi:10.69719/ros.v8.872
Lapka, M. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.062 · Cited by 1
Ling, C., Ming, T. S., Arasoo, J., & Dominic, N. A. (2025) · Springer eBooks · doi:10.1007/978-981-97-7640-5_129
Lee, Y., Park, J.-H., Lee, N.-K., Kim, J.-E., Lee, H.-C., & Kang, M.-H. (2025) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2025.46.5.1068
Role of Hormone Replacement Therapy in Managing Menopausal Mental Health
Mondal, S., Mandal, S., Bhat, S., Aalpona, F. T. Z., & Kamrul-Hasan, A. B. M. (2025) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_36_25
Hypopituitarism, causes, diagnosis, management and mortality
Fountas, A., Effraimidis, G., & Karavitaki, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00308-3 · Cited by 1
de Oliveira, A. L. M. L., Ribeiro, C. M., Agati, L. B., Berta, F., Barradas, C. A. A., Oliveira, S. C., Tukiyama, C. A., Maciel, B. A., Emanuel, A. C., Socca, E. A. R., et al. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002687
“4,47,48 In women who cannot monitor changes in bleeding patterns, the emergence of these symptoms — driven by declining ovarian estrogen production — often serves as the fi rst clinical indicator of menopause.”
Estrogen therapies enhance mammary carcinogenesis in aging gerbil females under endocrine disruption
Ruiz, T. F. R., Silva, S. B., Grigio, V., Rahal, P., Calmon, M. D. F., Vilamaior, P. S. L., Leonel, E. C. R., & Taboga, S. R. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112720
Lialy, H. E., Mohamed, M. A., AbdAllatif, L. A., Khalid, M., & Elhelbawy, A. (2024) · Figshare · doi:10.6084/m9.figshare.26603056
Jang, D., Lee, E., Lee, S., Kwon, Y., Kang, K. S., Kim, C.-E., & Kim, D. (2022) · Figshare · doi:10.6084/m9.figshare.19759778
Marian, I. R., Goff, M., Williams, J. A. E., Gulati, M., Chester‐Jones, M., Francis, A., Watson, M., Vincent, T. L., Woollacott, S., Mackworth-Young, C. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14843244
Impact of Menopausal Hormone Therapy on Brain Health in Postmenopausal Women, a Pilot Study
Fratantoni, J. M., DeNeui, T., Chang, Z., Venza, E. E., Wigginton, J. G., Spence, J. S., & Chapman, S. B. (2025) · Women s Health Reports · doi:10.1177/26884844251399085 · Cited by 1
Metabolic Changes and Menopause
Spremović-Radjenović, S. (2025) · Science, Art and Religion. · doi:10.5005/jp-journals-11005-0123
Menopausal Hormone Therapy—Transdermal or Oral
Hadžić, D., & Bolanča, I. (2025) · Science, Art and Religion. · doi:10.5005/jp-journals-11005-0125
Vasomotor Symptoms in Menopause: Modern Perspectives and Emerging Therapies
Jandrić, I., & Mašić, P. (2025) · Science, Art and Religion. · doi:10.5005/jp-journals-11005-0114
Amanzai, H., Kokorelias, K. M., Beltrano, B., Hannem, E., Pinney, J., Zeng, L., Metersky, K., Nishi, S. K., Stafford, A., & Hill, J. S. (2026) · Women · doi:10.3390/women6010008 · Cited by 1
“Other treatments include, but are not limited to, bisphosphonates for bone density [18], or selective serotonin reuptake inhibitors (SSRIs), Gabapentinoids, Clonidine, and Oxybutynin for VMSs [21,22].”
Mangla, M., Kumar, N., Kanikaram, P. K., Srirambhatla, A., & Bukke, N. (2026) · Current Women s Health Reviews · doi:10.2174/0115734048401172251112115653
Factors Associated With Hormone Replacement Therapy Use: A Systematic Review and Meta‐Analysis
Mtika, W. M., Allen, D. Z., Tranter, E., Glover, G., Hoang, J., Hillman, S., Coupland, C. A. C., Hippisley‐Cox, J., Tatnell, L., & Hirst, J. A. (2026) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.70160 · Cited by 1
Menopoz ve Diyabet: Kadın Sağlığında Çift Yönlü Bir İlişki
Bilgiç, D., & Sıdan, M. (2026) · İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi · doi:10.61399/ikcusbfd.1699367 · Cited by 1
Molefe‐Baikai, O. J., Kebotsamang, K., Manyeagae, G. D., Moshomo, T., Mawi, M., Mogaetsho, E., Gaolathe, T., Molebatsi, K., Kelepile, M., Kgotlaetsile, K., et al. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002760
Shin, J., Cho, G. J., Hadi, F. A., Kim, S., Snijder, R. J., Soliman, M., Chua, S. Y. L., & Lim, C. T. K. (2026) · Climacteric · doi:10.1080/13697137.2026.2615389
“Prescribing practices have evolved over the last few decades with better understanding of the risks and benefits of Ht [12–17].”
InfluentialSmith, E. E., Heintz, J. R., Chesnokova, A., & Taunk, N. K. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.02.211
Integrative approaches to breast oncology
Ahn, E. R., & Tripathy, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30194-0.00060-6
A Review of Traditional and Non-Traditional Cardiovascular Risk Factors in Women
Vasanthakumar, S. A., Paleri, S., Aldous, E., Khanna, S., Nandurkar, R., Davis, E., Lin, A., & Nerlekar, N. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s574244 · Cited by 1
“99,100 103 Although results from cohort studies are variable, overall evidence supports a relationship between menstrual irregularity and future cardiometabolic risk.”
Jörg, I., & Chronas, D. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06425-9
“…multidisciplinary consensus guidelines (AGO, DGGG) align with the aforementioned view: HRT should be avoided after breast cancer, and non-hormonal alternatives should be prioritized for managing menopausal symptoms following curative oncologic treat-ment (Wöckel et al. 2021 ; Stuenkel et al. 2015).”
Prevention and treatment of osteoporosis: causal or symptomatic?
Jan, Š. (2019) · Clinical Osteology · doi:10.36290/clo.2019.012 · Cited by 1
Sex-specific lymphatic responses to estrogen shape atherosclerosis in high-risk mice
Mesples, M., Lacroix, E., Tessier, N., Farhat, M., Milasan, A., Babran, S., Fernandez, C., Latendresse, T., Benoit, J., Long, V., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1699372
Vulval health in menopause: Understanding genito-urinary syndrome and the role of topical oestrogen
Elliott, T. (2026) · Independent Nurse · doi:10.12968/indn.2026.1.14
BMS consensus statement: Genitourinary Syndrome of Menopause (GSM)
Briggs, P. (2026) · Post Reproductive Health · doi:10.1080/20533691.2026.2629181
“Once the tissue quality has recovered, absorption of local estrogen decreases with minimal systemic effects and therefore smaller doses can be used to maintain the benefits achieved, hence a loading dose followed by a maintenance dose for most preparations [13].”
Approach to Hot Flashes: A Narrative Review
Nayan, A., Teja, S., Nareddy, S., Mahesh, K. V., Goyal, M., & Bansal, R. (2026) · Journal of Postgraduate Medicine Education and Research · doi:10.5005/jp-journals-10028-1760
Lesmes, I. B., García, C. M. A., Díaz‐Perales, A., Gil‐Izquierdo, Á., Nieto, G., Velasco, A. M. R., García‐Molina, V. A. A., & Chillerón, M. Á. C. (2026) · Food Risk Assess Europe · doi:10.2903/fr.efsa.2026.fr-00102
Liu, H., He, Y., Geng, W., Huang, Y., Gao, H., Zhai, Y., & Wang, Z. (2026) · BMC Women s Health · doi:10.1186/s12905-026-04460-9
Malhotra, N., Malhotra, N., Malhotra, J., Sharma, M., & Bansal, S. (2026) · Journal of SAFOMS · doi:10.5005/jp-journals-10032-0130
Menopause in Patients With Disabilities
Harris, J. A., & Kalpakjian, C. Z. (2026) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000001020
Shimizu, K., Nagashima, K., Iwakura, M., Nakao, M., Tanihara, S., Okawara, M., Fujino, Y., Jung, S., Kimura, T., Terauchi, M., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.108955
Menopausal Hormone Therapy and Cardiovascular Disease
Safwan, N., Saadedine, M., & Faubion, S. S. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_12
Navigating the Debate on Menopausal Hormonal Therapy and Practical Prescribing
Hofmann, G., & Santoro, N. F. (2026) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2026.03.007
17α-Estradiol: A mildly feminizing estrogen with sex-specific metabolic and lifespan benefits
Santín-Márquez, R., Fornalik, M., Janovic, S. R., Isola, J. V. V., Biswas, S., Sathiaseelan, R., Cox, J. E. J., Ocañas, S. R., & Stout, M. B. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103182 · Cited by 1
Clinical evidence on integrated Chinese-Western medicine for perimenopausal syndrome
Yang, R., Zhao, J., Li, H., Hu, Y., Liang, T., Zhang, J., Qin, Y., Chen, Y., Yang, Y., & Bian, Z. (2026) · Integrative Medicine Research · doi:10.1016/j.imr.2026.101357 · Cited by 1
“16,17 20 Therefore, integrated Chinese-Western medicine (ICWM) provides a rational therapeutic strategy by integrating the rapid symptom-targeted effects of Western medicine with the individualized and holistic regulatory effects of CM, thereby achieving complementary advantages, optimizing…”
Discontinuing and reintroducing hormone replacement therapy
Alsararatee, H. H. (2026) · Independent Nurse · doi:10.12968/indn.2026.5.19
Evaluation of breast risk at menopause: what impact on the use of menopausal hormone therapy?
Rodrigues, M. A. H., & Gompel, A. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.108998 · Cited by 1
Self-citationWang, Y., Liu, Y., Zeng, J., Wang, M., Li, Y., Wu, Y., Gao, J., & Chen, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1817851
Liu, C. C.-Y., König, C. S., & Ramachandran, S. (2026) · Endocrines · doi:10.3390/endocrines7020026
“Postmenopausal women experience reduced ovarian production of oestradiol and progesterone, with compensatory increases in gonadotropins such as follicle-stimulating hormone (FSH) and luteinising hormone (LH) due to loss of ovarian negative feedback [3–5].”
Bor, P., Bor, M. V., Juul, S. L., & Glavind‐Kristensen, M. (2026) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2882-1241
Bencivenga, P. A., Fort, N., Fugh‐Berman, A., & Scialli, A. R. (2026) · JRSM Open · doi:10.1177/20542704261455970 · Cited by 1
“54 Among women in the WHI randomised to CEE at age 50 – 59, 1129 women had bilateral salpingo-oophorectomy, and 2008 women had hysterectomy with retention of at least part of one ovary.”
CÖMERT, E. H., Doğan, Ü. K., Yıldırım, A. E., Özağaç, B., Doğruel, T., & Doğa, O. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002840
Psychosomatic Presentation of Menopause
Baral, G. (2026) · Obstetrics and gynecology. · doi:10.5772/intechopen.1016615
Cizmáriková, R., Valentová, J., Polakovičová, M., & Habala, L. (2026) · European Pharmaceutical Journal · doi:10.2478/afpuc-2026-0003
“The phenol group is found in the structure of the hormonal contraceptive estrogen (Stuenkel et al., 2015), the thyroid hormone thyroxine (Mondal et (Cheng et al., 2025).”
Lund-Jacobsen, T., Martino, G., Pedersen, C., Piil, K., & Schwarz, P. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45158
Sleep Disorders in Pelvic and Women’s Health
Özkutlu, Ö., & İnal, Ö. (2026) · Springer eBooks · doi:10.1007/978-3-032-28741-0_25
Physiotherapy and Rehabilitation in Menopause
Demirtürk, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-28741-0_21
Heidenreich, S., Simoncini, T., Cutts, K. N., Krucien, N., Kim, J., Todorova, L., Walker, J., Kristjansson, C., & Hillard, T. (2026) · Patient · doi:10.1007/s40271-026-00831-4
“However, HT is contraindicated in women with current or a history of breast or endometrial cancer, coronary heart disease, stroke and thromboembolic diseases [14, 16, 17].”
Overlap Between Heart Failure and Menopause: Diagnostic Challenges and Clinical Implications
Kwan, T. N., Yan, A., Jain, P., Raju, H., & Muthiah, K. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.05.011 · Cited by 1
Navigating the storm: Understanding and managing depression during menopause in women
Saini, A., Verma, I., & Bhatia, R. (2026) · Scripta Medica · doi:10.5937/scriptamed57-61696
“22 Worsley et al performed a systematic review and concluded that vasomotor symptoms are positively correlated to depression among women.”
Sankar, K., Kanagaraja, A., Narayanasamy, A., Ganesh, M. R., Kannan, A., Lakshmi, P. T. V., Raman, P., & Arunachalam, A. (2026) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2026.109397
Canino, M. C., Cohen, B. E., Byrd, C., & Gahche, J. J. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002853
Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database
Wei, S., Song, Q., & Wang, L. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05773-0
Yasui, Y., Shimizu, A., Tanabe, M., Byambadorj, N., Ezure, K., Endo, K., Kawano, M., Sekitani, T., Kodama, M., & Sawada, K. (2026) · Women s Health Reports · doi:10.1177/26884844261476393
Reassurance through normalization inadvertently suppresses treatment
Lawal, S., Chew, B., & Amir, O. (2026) · Nature Human Behaviour · doi:10.1038/s41562-026-02542-0
Role of menopause in the development of cardiovascular disease in women
Das, S., Wang, W., & Kunadian, V. (2026) · Open Heart · doi:10.1136/openhrt-2026-004200
“95 These findings are in accordance with current guideline recommendations for the hormonal treatment of VMS. 96 The Early versus Late Postmenopausal Treatment with Estradiol randomised control trial which evaluated early versus late postmenopausal treatment with estradiol, involved 643 women and found that oral estra…”
InfluentialPatel, A. J., Karandikar, A. N., Miron-Ocampo, A., Karandikar, N. J., & Mangalam, A. K. (2026) · ImmunoHorizons · doi:10.1093/immhor/vlag046
Menopausal hormone therapy in Türkiye: physician knowledge and practice gaps
Housseın, M., Yetkin, N. A., & Güneş, A. C. (2026) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20260307
“However, global prescribing patterns changed dramatically after publication of the Women’s Health Initiative (WHI) trials in 2002, which reported increased cardiovascular and breast cancer risks in older women initiating combined therapy many years after menopause 3,4 .”
InfluentialLi, Y., Zhai, L., Wang, L., Deng, S., Zhao, B., Niu, H., Zhang, L., & Gao, X. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002887
Tsikouras, P., Pagkaki, C., Bothou, Α., Lambrinos, D., Chalkidou, A., Deuteraiou, D., Kritsotaki, N., Oikonomou, E., Kourti, V., Tsikouras, N., et al. (2026) · Obstetrics and gynecology. · doi:10.5772/intechopen.1017694
Cancer Risk in Premature Ovarian Insufficiency: Current Evidence and Clinical Implications
Devanbu, V. G. C., John, J. B., & Karpagam, K. V. (2026) · Journal of Mid-life Health · doi:10.4103/jmh.jmh_113_26
Drysdale, K., Karasu, Y., & Watson, L. (2026) · Health Promotion International · doi:10.1093/heapro/daag132
“Menopause is clinically defined in relation to the date of the final menstrual period and consequent cessation of ovarian function (Stuenkel et al .”
The Association Between Sleep Disturbance and Sexual Dysfunction in Menopause: A Systematic Review
Ashar, D. A., Kabel, K. E., Fertig, M. R., Bhardwaj, A., Kundu, R. S., & Stanton, A. M. (2026) · Current Sexual Health Reports · doi:10.1007/s11930-026-00429-9
TERAPIA HORMONAL NO CLIMATÉRIO: INDICAÇÕES, CONTRAINDICAÇÕES, BENEFÍCIOS E RISCOS
Campos, K. K. L. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i9.8950
Multiplex ovarian hormone monitoring in sweat using a dual-aptamer wearable sensor
Lee, Y. S., Ye, C., Yeom, J., Chen, Y., Li, J., Min, J., Wang, M., & Gao, W. F. (2026) · Device · doi:10.1016/j.device.2026.101299
“15,21 For example, prolonged exposure to unopposed E2 increases the risk of endometrial hyperplasia during HRT, while menstrual migraine is associated with dynamic E2 withdrawal occurring within the broader context of ovarian hormone fluctuations.”
Obhrai, S., Shenoy, S., & ARORA, M. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002894
Hormonal Options for Perimenopause: A Clinician Toolkit
Piasta, J., & Zewail, A. (2026) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006436 · Cited by 2
Bonaventura, I., Weigand, I., Isidori, A. M., Kroiß, M., & Reincke, M. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag035
Liang, C., Dobson, A. J., Doust, J. A., Ribeiro, L. W., & Mishra, G. D. (2026) · Diabetologia · doi:10.1007/s00125-026-06856-6 · Cited by 1
Symptomatische Postmenopause – Hormonelle und nicht-hormonelle Interventionen
Doll, I., Schaudig, K. T., & Schwenkhagen, A. (2026) · Die Gynäkologie · doi:10.1007/s00129-026-05548-x
Feminist Fabulations for Reworlding Menopause Care
Mohammadi, O., Maurer, B., & Fuchsberger, V. (2026) · Nordic Conference on Human-Computer Interaction · doi:10.1145/3821402.3830163
Rusk, K., Acevedo‐Alvarez, M., Whalen, M. C. R., Reinhardt, N. L. S., Norman, M. C., & Matthews, G. J. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002890
Olivola, M., Agosta, A., Consonni, A., Filippis, R. D., Regispani, F., Reina, L. M., Martiadis, V., Fantini, G., Sanna, B., Calò, L., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207956
“…emphasizing individualized assessment of menopausal symptoms and the benefits and risks of HRT. Treatment decisions take into account symptom burden, particularly vasomotor symptoms, medical history, contraindications, and patient preferences, rather than a single affective complaint [13,14].”
Use of vaginal estrogens in urogynecology: current evidence, controversies and clinical applications
Singh, P., Pancholy, J., & Pancholy, A. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001157
Kruijt, M., de Mutsert, R., Vlieg, A. V. H., Rosendaal, F. R., Hillebrand, J. J., den Heijer, M., & Heijboer, A. C. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag194
Ranatunga, V. S., Sutarsa, N., Vargas, N., Miles, K. H., & Estaphan, S. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002899
Reappraising the safety of menopausal hormone therapy for women—implications for the clinic
Hirschberg, A. L. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag404
Impacto do treinamento resistido na saúde física e qualidade de vida de mulheres em pós-menopausa
de Lima, B. Â., de Lima, P. M., de Fontes, P. A. D. S., & Pinto, A. A. (2026) · Research Society and Development · doi:10.33448/rsd-v15i4.50935
Vataman, E., & Cernetchi, O. (2026) · Moldovan Journal of Health Sciences · doi:10.52645/mjhs.2026.3.06
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.